Monitor commercial uptake of the new pediatric doses and the pending sNDA decision for lower-weight children (13kg to <27kg). The label expansion incrementally increases Joenja's total addressable market, though APDS affects only 1-2 per million people.
Price Chart
Executive Summary
FDA approved Pharming's Joenja (leniolisib) for children aged 4-11 with APDS, expanding the label to younger pediatric patients. This is the first FDA-approved treatment for this age group, expected to be available in October 2026. The approval is supported by Phase III data showing improvements in lymphadenopathy and naïve B cells.
Key Facts
- FDA approved sNDA for Joenja (leniolisib) for children aged 4-11 weighing ≥27 kg with APDS
- First FDA-approved treatment for this pediatric APDS population in the US
- New 40 mg and 50 mg twice-daily doses expected to be available in October 2026
- Approval supported by Phase III open-label study showing reduced lymphadenopathy and increased naïve B cells over 12 weeks
- Safety profile consistent with prior experience; no drug-related serious adverse events observed
- Separate sNDA submitted for lower doses for children weighing 13 kg to <27 kg
Financial Impact
Expands addressable pediatric population; no specific revenue guidance provided
Risk Factors
- Small patient population (APDS affects 1-2 per million) limits revenue impact
- Potential competition from other PI3Kδ inhibitors in development
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 28w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers